Fred Hutchinson Cancer Center is a world leader in Myelodysplastic Syndrome (MDS) research. Our experts are developing innovative ways to detect and diagnose MDS, unraveling how MDS progresses to ...
The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes. A new report explains why patients with myelodysplastic syndromes (MDS) become ...
Adding venetoclax to oral decitabine-cedazuridine improves responses in higher-risk MDS and CMML patients. Inqovi, an oral decitabine-cedazuridine combination, was FDA approved in 2020 for primary or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results